- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Emblem Sees Significant Rise in Patient Acquisition
Emblem Corp. (TSXV:EMC) (“Emblem” or the “Company”) is pleased to announce that the Company has successfully ramped up its patient acquisition program resulting in a total of 2,091 active and pending patients (net of expired and disabled registrations) having registered since the opening of its patient fulfillment website in late November, 2016. Patient acquisition has been progressively accelerating with 49 patients registered in November, 157 in December, 437 in January, 691 in February and 553 in March to date with a further 246 registrations pending verification.
Emblem Corp. (TSXV:EMC) is pleased to announce that the Company has successfully ramped up its patient acquisition program resulting in a total of 2,091 active and pending patients (net of expired and disabled registrations) having registered since the opening of its patient fulfillment website in late November, 2016. Patient acquisition has been progressively accelerating with 49 patients registered in November, 157 in December, 437 in January, 691 in February and 553 in March to date with a further 246 registrations pending verification.
“We are extremely pleased with the progress made since the launch of our website to attract and register patients at such an accelerated rate,” noted Gordon Fox, CEO of Emblem Corp. “We believe that our patient growth is a favorable reflection on the quality of our cannabis products, our customer service and our physician and patient communication strategies.”
Emblem is also pleased to report that GrowWise Health, Emblem’s cannabis healthcare vertical, is continuing to expand its clinic network. “GrowWise clinics and cannabis education centres promise to become an important source of patients for Emblem,” says Fox.
With physicians becoming more comfortable referring patients and embracing cannabis as an alternative treatment, GrowWise is quickly expanding its presence across Canada. Thus far in 2017, four new GrowWise locations have opened their doors to patients across Ontario and in British Columbia, bringing the total to 11 clinics, with more locations scheduled to open across the country in the coming months.
About Emblem
Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) through its wholly owned subsidiary, Emblem Cannabis Corporation, to cultivate and sell medical cannabis. Emblem carries out its principal activities producing cannabis from its facilities in Paris, Ontario pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations.
Click here to learn more about Emblem Corp. (TSXV:EMC).
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.